Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia

Leukemia Research

Volumn 34, Issue 7, 2010, Pages 858-863

  Kanojia, Deepika ^a   Garg, Manoj ^a   Saini, Shikha ^a   Agarwal, Sumit ^a   Kumar, Rajive ^b   Suri, Anil ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Biomarkers; Cancer testis antigen; Chronic myeloid leukemia; Immunotherapy; SPAG9

Indexed keywords

MESSENGER RNA; ONCOPROTEIN; SPERM ASSOCIATED ANTIGEN 9; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BLAST CRISIS; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOTHERAPY; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 77952953455     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.01.017     Document Type: Article

References (31)

1. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. New Eng J Med 1999, 341:164-172.
2. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
3. Gajewski J.L., Robinson P. Do affluent societies have the only options for the best therapy?. Leukemia 2007, 21:387-388.
4. Suri A. Cancer testis antigens-their importance in immunotherapy and in early detection of cancer. Expert Opin Biol Ther 2006, 6:379-389.
5. Greiner J., Schmitt M. Cancer testis/germline antigens (CT/CG-antigens) in leukemias. Leukemia Res 2007, 31:1-3.
6. Fiszer D., Kurpisz M. Major histocompatibility complex expression on human, male germ cells: a review. Am J Rep Immunol 1998, 40:172-176.
7. Westbrook V.A., Schoppee P.D., Diekman A.B., Klotz K.L., Allietta M., Hogan K.T., et al. Genomic organization, incidence, and localization of the SPAN-X family of cancer-testis antigens in melanoma tumors and cell lines. Clin Cancer Res 2004, 10:101-112.
8. 2-terminal kinase interacting protein. Biochem J 2005, 389:73-82.
9. Garg M., Chaurasiya D., Rana R., Jagadish N., Kanojia D., Dudha N., et al. Sperm associated antigen 9 (SPAG9), a novel cancer testis antigen is potential target for immunotherapy in epithelial ovary cancer. Clin Cancer Res 2007, 13:1421-1428.
10. Garg M., Kanojia D., Khosla A., Dudha N., Sati S., Chaurasiya D., et al. Sperm associated antigen 9 is associated with tumor growth, migration and invasion in renal cell carcinoma. Cancer Res 2008, 68:8240-8248.
11. Kanojia D., Garg M., Gupta S., Gupta A., Suri A. Sperm associated antigen 9 (SPAG9), a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:630-639.
12. Garg M., Kanojia D., Salhan S., Suri S., Gupta A., Lohiya N.K., Suri A. Sperm-associated antigen 9 (SPAG9) is a biomarker for early cervical carcinoma. Cancer 2009, 115:2671-2683.
13. Garg M., Kanojia D., Suri S., Gupta S., Gupta A., Suri A. Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab 2009, 94:4613-4618.
14. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
15. Savona M., Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341-350.
16. Melo J.V., Chuah C. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Hematology 2008, 1:427.
17. Kantarjian H.M., Giles F., Quintás-Cardama A., Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007, 13:1089-1097.
18. Gannage M., Abel M., Michaellet A.S., Delluc S., lambert M., Giraudier S., et al. Ex vivo characterization of multiepitopic tumor specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and cellular immunotherapy. J Immunol 2005, 174:8210-8218.
19. Pinilla-Ibarz J., Cathcart K., Krontsvit T., Soignet S., Bocchia M., Caggiano J., et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint peptides generates specific immune responses. Blood 2000, 95:1781-1787.
20. Lancet Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., et al. Effect of p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005, 365:657-662.
21. Jain N., Reuben J.M., Kantarjian H., Li C., Gao H., Lee B.N. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease. Cancer 2009, 115:3924-3934.
22. Grünebach F., Mirakaj V., Mirakaj V., Müller M.R., Brümmendorf T., Brossart P. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. Cancer Res 2006, 66:5892-5900.
23. Wang Z., Zhang Y., Mandal A., Zhang J., Giles F.J., Herr J.C., Lim S.H. The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies. Clin Cancer Res 2004, 10:6544-6550.
24. Wang Z., Zhang Y., Liu H., Salati E., Chiriva-Internati M., Lim S.H. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 2003, 101:955-960.
25. Adams S.P., Sahota S.S., Mijovic A., Czepulkowski B., Padua R.A., Mufti G.J., Guinn B.A. Frequent expression of HAGE in presentation chronic myeloid leukaemias. Leukemia 2002, 16:2238-2242.
26. Schmitt M., Li L., Giannopoulos K., Chen J., Brunner C., Barth T., Schmitt A., et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 2006, 34:1709-1719.
27. Roman-Gómez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., Jose-Eneriz E.S., et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica 2007, 92:153-162.
28. Roman-Gómez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Navarro G., Jose-Eneriz E.S., et al. Epigentic regulation of PRAME gene in chronic myeloid leukemia. Leukemia Res 2007, 31:1521-1528.
29. Carter P., Smith L., Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocrine-Related Cancer 2004, 11:659-687.
30. Lim S.H., Periman P., Klug P., Weidanz J., Whitton V., Chiriva-Internati M., et al. Defining tumor antigens: mRNA, protein or cytotoxicity?. Trends Immunol 2002, 23:236-237.
31. Quintarelli C., Dotti G., Angelis B.D., Hoyos V., Mims M., Luciano L. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008, 112:1876-1885.